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Abstract. 
 
Carrier vesicle generation from donor mem-
branes typically progresses through a GTP-dependent 
recruitment of coats to membranes. Here we explore 
the role of ADP ribosylation factor (ARF) 1, one of the 
GTP-binding proteins that recruit coats, in the produc-
tion of neuroendocrine synaptic vesicles (SVs) from 
PC12 cell membranes. Brefeldin A (BFA) strongly and 
reversibly inhibited SV formation in vivo in three dif-
ferent PC12 cell lines expressing vesicle-associated 
membrane protein–T Antigen derivatives. Other mem-
brane traffic events remained unaffected by the drug, 
and the BFA effects were not mimicked by drugs 
known to interfere with formation of other classes of 
vesicles. The involvement of ARF proteins in the bud-
ding of SVs was addressed in a cell-free reconstitution 
system (Desnos, C., L. Clift-O’Grady, and R.B. Kelly. 
1995. 
 
J. Cell Biol. 
 
130:1041–1049). A peptide spanning 
the effector domain of human ARF1 (2–17) and recom-
binant ARF1 mutated in its GTPase activity, both in-
hibited the formation of SVs of the correct size. During 
in vitro incubation in the presence of the mutant ARFs, 
the labeled precursor membranes acquired different 
densities, suggesting that the two ARF mutations block 
at different biosynthetic steps. Cell-free SV formation 
in the presence of a high molecular weight, ARF-depleted 
fraction from brain cytosol was significantly enhanced 
by the addition of recombinant myristoylated native 
ARF1. Thus, the generation of SVs from PC12 cell 
membranes requires ARF and uses its GTPase activity, 
probably to regulate coating phenomena.
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1.
 
 Abbreviations used in this paper
 
: ARF, ADP ribosylation factor; BFA,
brefeldin A; COPI and COPII, coat proteins I-II; HMW, high molecular
weight; SV, synaptic vesicle; TAg, T Antigen; VAMP, vesicle-associated
membrane protein.
 
G
 
eneration
 
 of carrier vesicles from plasma mem-
brane or intracellular membranous compartments
involves at least two components, GTP-binding
proteins and coats (Rothman and Wieland, 1996; Schek-
man and Orci, 1996). A particularly widespread protein
that regulates coat assembly on intracellular membranes is
ADP ribosylation factor (ARF)
 
1
 
 1, a small GTP-binding
protein (Donaldson and Klausner, 1994; Boman and Kahn,
1995). The budding of vesicles from Golgi cisternae can be
fully reconstituted in the presence of ARF1 and coatomer
(COPI) (Ostermann et al., 1993; Donaldson and Klausner,
1994; Boman and Kahn, 1995; Rothman and Wieland,
1996). ARF1 recruits coatomers to the budding vesicle and
couples uncoating to fusion with target membranes (Oster-
mann et al., 1993; Tanigawa et al., 1993). ARF1 is also re-
quired for the recruitment of COPI to vesicles budding
from the ER (Bednarek et al., 1995). A hallmark of
ARF1-mediated processes is their sensitivity to the fungal
metabolite brefeldin A (BFA).
The GDP–GTP exchange activity that replaces GDP
bound to ARF proteins with GTP is inhibited by BFA
(Donaldson et al., 1992; Helms and Rothman, 1992). The
GDP form of ARF1 is unable to bind membranes and
consequently, to recruit coats (Robinson and Kreis, 1992;
Donaldson and Klausner, 1994). The selectivity of BFA is
such that, if a membrane traffic event is sensitive to BFA,
it is predicted to require ARF proteins. Inhibition of intra-
Golgi and ER to Golgi traffic by BFA probably involves
the COPI coatomers. BFA also interferes with coats other
than COPI, especially those involved in budding from TGN.
Thus it inhibits the formation of vesicles from the TGN
(Simon et al., 1996) and causes the redistribution of assem-
bly protein 1 and clathrin to the cytosol (Robinson and Kreis,
1992). Post-Golgi trafficking of the mannose-6-phosphate
receptor (Wood et al., 1991) and the maturation of secre-
tory granules (Dittie et al., 1996) are also sensitive to BFA.
In addition to clathrin and COPI, BFA affects the recruit-
ment of other “coating” molecules, such as the p47–
 
b
 
NAP
complex (Simpson et al., 1996; Dell’Angelica et al., 1997)
and p200 (Narula and Stow, 1995) to TGN membranes.
Some endocytotic pathways are also sensitive to BFA.
For example, the delivery of polyimmunoglobulin A (pIgA)
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to plasma membrane from the specialized apical endo-
some in epithelial MDCK cells, or from dendritic endo-
somes in hippocampal neurons, is inhibited by BFA (Hun-
ziker et al., 1991; Barroso and Sztul, 1994). BFA-sensitive
recruitment of COP1-related proteins and ARF proteins
to endosomes has also been reported (Whitney et al., 1995;
Cavenagh et al., 1996).
The formation of synaptic vesicles at nerve terminals is a
specialized endocytotic pathway that has many similarities
to the formation of carrier vesicles from Golgi mem-
branes. In this case, the donor membrane for synaptic ves-
icle formation is the plasma membrane or the endosome
(De Camilli and Takei, 1996). Morphological evidence
strongly suggests that synaptic vesicles are generated in
nerve terminals through a coat-dependent mechanism
(Shupliakov et al., 1997). In lysed nerve terminals, recruit-
ment of dynamin and clathrin coats to membranous or-
ganelles is modulated by nonhydrolyzable GTP analogues
(Takei et al., 1996). Cell-free reconstitution assays of neu-
roendocrine synaptic vesicle (SV) formation in PC12 cell
extracts showed that GTP
 
g
 
S blocks the generation of
properly sized SVs (Desnos et al., 1995), but the identity of
the GTP-binding protein or proteins was not determined.
In this paper, we show that reagents that interfere with
the cycling of ARF1 between cytosol and membranes
block SV formation in neuroendocrine PC12 cells. SV for-
mation was reconstituted in vitro using recombinant
ARF1 and a cytosol-derived high molecular weight frac-
tion. Since SV production in vitro is from an endocytotic
pool, these results suggest that coating mechanisms associ-
ated with ER and Golgi biosynthetic pathways are also as-
sociated with at least one endocytotic pathway.
 
Materials and Methods
 
125
 
I-labeled Na and ECL reagents were obtained from Amersham Corp.
(Arlington Heights, IL). Iodogen came from Pierce Chemical Co. (Rockford,
IL). ATP, GTP
 
g
 
S, creatine phosphate, creatine kinase, and Sephadex
G25 spun columns were purchased from Boehringer Mannheim Biochem-
icals (Indianapolis, IN). DEAE Sephacel, Superose 6, ProtG-Sepharose 4
Fast Flow, and BL21 
 
Escherichia coli
 
 strain were obtained from Pharma-
cia Biotech AB (Uppsala, Sweden). Ultrogel AcA 54 was from Biosepra
(Marlborough, MA). Brefeldin A was purchased from Epicentre Technol-
ogies (Madison, WI). Bafilomycin A1 was obtained from Calbiochem-
Novabiochem Corp. (LaJolla, CA). Illimaquinone and avarol were kindly
provided by Dr. V. Malhotra (University of California, San Diego, CA).
Cell culture media and reagents were obtained from the University of Cal-
ifornia Cell Culture Facility (San Francisco, CA). Geniticin (G418) and
isopropylthio-
 
b
 
-
 
d
 
-galactoside were obtained from GIBCO BRL (Gaith-
ersburg, MD). All the other reagent grade chemicals were purchased ei-
ther from Sigma Chemical Co. (St. Louis, MO), Fisher Scientific Co.
(Fairlawn, NJ), or Calbiochem-Novabiochem Corp. Female Sprague-
Dawley rats were from Bantin and Kingman (Fremont, CA).
 
Peptides
 
A 16–amino acid peptide (GNIFANLFKGLFGKKE) corresponding to
residues 2–17 of the human ARF1 NH
 
2
 
 terminus (ARF 2–17 peptide), and
a scrambled peptide of identical composition (FLKANGIGLNEKKGFF)
(Chen and Shields, 1996) were either a gift of Dr. D. Shields (Albert Ein-
stein College of Medicine, New York) or were purchased from Chiron
Mimotopes (San Diego, CA).
 
Cell Culture
 
PC12 cell lines stably transfected with rat vesicle-associated membrane
protein–T Antigen (VAMP-TAg) and with the mutants N49A and del 61–
70 were grown in DME H-21 media supplemented with 10% horse serum,
5% FCS, 100 U/ml penicillin and 100 
 
m
 
g/ml streptomycin, and with 250
 
m
 
g/ml G418. The cells were treated for 24 h before the experiments with 6
mM sodium butyrate to induce the expression of the different VAMP con-
structs as described (Grote et al., 1995).
 
Cell Labeling and Subcellular Fractionation
 
PC12 cells containing the different VAMP-TAg constructs were labeled
with 
 
125
 
I-KT3 mAb against the TAg epitope tag following the methods of
Desnos et al. (1995). Briefly, confluent dishes of cells were washed at 0
 
8
 
C
with labeling buffer (PBS supplemented with 3% BSA, 0.3 mM CaCl
 
2
 
, 0.3
mM MgCl
 
2
 
, and 1 mg/ml glucose), labeled in the same buffer at 0
 
8
 
C for 15
min, and then transferred at 15
 
8
 
C for 40 min. After labeling, the cells were
extensively washed in the same buffer, scraped, and sedimented at 800 
 
g
 
for 5 min. To examine the effect of reagents on the in vivo generation of
SVs, cells were first labeled at 15
 
8
 
C and then treated in DME H-21, 10
mM Hepes, pH 7.4, for 15 min at 0
 
8
 
C with different drugs, and then trans-
ferred to 37
 
8
 
C for times indicated. Similar results were obtained by prein-
cubating cells with the drugs for 30 min at 15
 
8
 
C before warming them. La-
beled cells were chilled at 0
 
8
 
C, and then washed and pelleted as described
above. Cell pellets were gently resuspended in intracellular buffer (38 mM
potassium aspartate, 38 mM potassium glutamate, 38 mM potassium glu-
conate, 20 mM potassium MOPS, pH 7.2, 5 mM reduced glutathione, 5
mM sodium carbonate, 2.5 mM magnesium sulfate) containing protease
inhibitors. Homogenizations were performed as described using a ball
bearing homogenizer (cell cracker; European Molecular Biology Labora-
tory, Heidelberg) with 12 
 
m
 
m clearance. For in vivo experiments, the dif-
ferent conditions in the same experiment were normalized by seeding
equal amounts of cells and by loading equal amount of homogenate pro-
teins during subcellular fractionation.
A postnuclear supernatant (S1; 1,000 
 
g
 
 for 5 min) was sedimented at
27,000 
 
g
 
 for 35 min, and the supernatant generated (S2) was used to iden-
tify SVs by velocity sedimentation. S2 (250 
 
m
 
l, 3–5 mg/ml) were loaded
onto 5–25% glycerol gradients prepared in intracellular buffer over a 50%
sucrose cushion, and then spun at 218,000 
 
g
 
 for 75 min in a rotor (SW55;
Beckman Instruments, Inc., Palo Alto, CA). Fractions (17 and 18) were
collected from the bottom and counted on a gamma counter. For either in
vivo or cell-free reactions, the amount of labeled synaptic vesicles gener-
ated was determined by integration of the total cpm in the SV peak (frac-
tions 8–13) minus the background cpm determined by integration of the
same fractions in parallel reactions, kept at 4
 
8
 
C.
 
In Vitro Budding Assay
 
VAMP-TAg/N49A PC12 cells were labeled at 15
 
8
 
C as described above.
The assay was performed as described by Desnos et al. (1995). Aliquots of
1 mg of homogenate were incubated for 30 min at 37
 
8
 
 or 4
 
8
 
C in the pres-
ence of an ATP regenerating system (1 mM ATP, 8 mM creatine phos-
phate, 5 
 
m
 
g/ml creatine kinase), and 1 or 3 mg/ml of rat brain cytosol pre-
pared as described (Desnos et al., 1995). ARF1 was removed from rat
brain cytosol using a Superose 6 sizing column, preequilibrated in intracel-
lular buffer, as described (Waters et al., 1991; Stamnes and Rothman, 1993).
In reactions containing peptides or recombinant ARF1 proteins, mixtures
were preincubated for 15 min at 0
 
8
 
C before warming, whereas those con-
taining antibodies or glutathione-S-transferase (GST) fusion proteins were
kept at 0
 
8
 
C for 3 h. The reactions were stopped by chilling to 0
 
8
 
C for 10
min before fractionation.
Clathrin heavy chains were quantitatively removed from cytosol using
the X22 mAb (Brodsky, 1985). Briefly 60 
 
m
 
g of antibody were bound
overnight to 40 
 
m
 
l of packed protein G–Sepharose in 0.5 ml of intracellu-
lar buffer. Unbound Ig was extensively washed in intracellular buffer and
the X22 affinity matrix was incubated with 0.8 mg of cytosol for 2 h at 4
 
8
 
C
with gentle rocking. The gel was spun and the cytosol recovered for in
vitro reactions. The beads were washed from cytosolic proteins and the
clathrin bound to them, and clathrin remaining in the cytosol was deter-
mined by immunoblotting using the TD.1 anti-clathrin heavy chain anti-
body (Nathke et al., 1992). Blots were performed using the enhanced
chemiluminescence (Amersham Corp.) system. The amount of clathrin
remaining in the cytosol was determined after exposing films for several
times. Images were acquired in a digital image system (IS1000; Alpha In-
notech Corp., San Leandro, CA) and quantified using the National Insti-
tutes of Health Image 1.60 program. The clathrin removed was 90–95% of
the total. The cytosol protein concentration before and after the depletion
remained constant. 
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Expression and Purification of Recombinant Proteins
 
Wild-type, Q71L, and T31N mutant human ARF1 cDNAs subcloned in
the pET11d expression vector and yeast 
 
N
 
-myristoyl transferase
(pBB131) were kindly provided by Dr. D. Shields. Native and mutant pro-
teins were coexpressed with 
 
N
 
-myristoyl transferase in BL21 
 
E. coli
 
 strain
and purified as described (Randazzo et al., 1992). Myristoylated recombi-
nant proteins were extensively dialyzed against intracellular buffer, con-
centrated to 2–3 mg/ml in a Centriprep 10 (Amicon Corp., Danvers, MA).
Aliquots were flash frozen in liquid N
 
2
 
, and stored at 
 
2
 
70
 
8
 
C. Purity, as-
sessed by SDS-PAGE and Coomassie blue staining, was 
 
z
 
80%. The iden-
tity of the ARF1 protein was confirmed by immunoblot using the 1D9
mAb (kindly provided by Dr. R. Kahn, Emory University, Atlanta, GA).
It also bound to PC12 membranes in the presence of GTP
 
g
 
S (Walker et
al., 1992). WBP1-GST fusion proteins were purified following manufac-
turer’s instructions. Recombinant proteins were concentrated in a Cen-
triprep 30 (Amicon Corp.) to 1–3 mg/ml and extensively dialyzed against
intracellular buffer.
 
Measurements of VAMP-TAg/N49A Endocytosis and 
Transferrin Recycling
 
Endocytosis of VAMP-TAg/N49A protein was assessed as described
(Grote and Kelly, 1996). Cells were plated 2 d before the assay on poly-
 
d
 
-lysine–coated dishes. Surface labeling was performed with 
 
125
 
I-KT3 (3.3
 
m
 
g/ml) for 2 h at 0
 
8
 
C. N49A/PC12 cells were extensively washed in label-
ing buffer, and then incubated for 15 min at 0
 
8
 
C either in the absence or
presence of BFA (5 
 
m
 
g/ml) in DME H-21, 10 mM Hepes, pH 7.4, before
warming to 37
 
8
 
C for different times. Endocytosis was stopped at 0
 
8
 
C for
10 min. Antibody remaining on the cell surface was removed by acid strip-
ping with labeling buffer supplemented with 30 mM glycine adjusted to
pH 2.4. Acid-resistant antibody was collected by lysing the cells in 2M
NaOH. Calculation and expression of the results were done as described
(Grote and Kelly, 1996).
N49A/PC12 cells were incubated in serum-free media for 90 min at
37
 
8
 
C before labeling. 
 
125
 
I-rat transferrin (0.2 
 
m
 
g/ml) was bound for 15 min
at 0
 
8
 
C and internalized at 15
 
8
 
C for 40 min as described above. Unbound
transferrin was washed at 0
 
8
 
C in DME H-21 media, 0.2% BSA, 10 mM
Hepes, pH 7.4. Surface-bound ligand was removed at 0
 
8
 
C by three washes
of 6 min in mild acidic buffer (0.5 M NaCl, 50 mM MES, pH 5.0) (Martys
et al., 1995), followed by three washes in PBS, 0.3 mM CaCl
 
2
 
, 0.3 mM
MgCl
 
2
 
. These washes removed 70–80% of the surface-associated 
 
125
 
I-rat
transferrin. N49A cells were then incubated at 0
 
8
 
C in DME H-21 media,
10 mM Hepes, pH 7.4, supplemented with 100 
 
m
 
g/ml of cold iron-loaded
rat transferrin in the presence of either methanol (0.001%) or BFA (5 
 
m
 
g/
ml) for 15 min at 0
 
8
 
C. Cells were then warmed for different times and the
reactions stopped at 0
 
8
 
C. 
 
125
 
I-rat transferrin that was released to the su-
pernatant, and that which remained cell associated, were both determined
after TCA precipitation.
 
Confocal Immunofluorescence Microscopy
 
Immunofluorescence procedures and confocal microscopy have been de-
tailed elsewhere (Bonzelius et al., 1994). N49A/PC12 cells were plated in
poly-
 
d
 
-lysine–coated Permanox
 
TM
 
 slides (Nunc Inc., Naperville, IL) 2 d
before staining. Cells were loaded in vivo with KT3 antibodies (10 
 
m
 
g/ml) in
labeling buffer and washed as mentioned above. To observe total VAMP-
TAg/N49A, cells were fixed in 4% paraformaldehyde in PBS. For the en-
docytosis assays, cells (before fixation) were acid stripped in uptake buffer
supplemented with 30 mM glycine adjusted at pH 2.4 as previously de-
scribed (Grote and Kelly, 1996). Fixed cells were permeabilized in 0.02%
saponin in PBS, 2% BSA, 1% fish skin gelatin, and incubated with affin-
ity-purified fluorescent-labeled goat anti–mouse IgG (Cappel Laborato-
ries, Malvern, PA). Observation and image acquisition were performed in
a Bio Rad MRC 600 confocal laser scanning microscope (Hercules, CA).
 
Other Procedures
 
KT3 mAbs and iron-loaded rat transferrin were iodinated in iodogen-
coated tubes according to Grote and Kelly (1996). Protein assays were
performed using the Bio-Rad Protein Assay Dye Reagent (Hercules, CA)
using BSA as standard.
 
Results
 
In Vivo SV Biogenesis is Reversibly Inhibited by BFA
 
To determine whether SV biogenesis is an ARF-mediated
process, the effect of BFA upon synaptic vesicle biogene-
sis in PC12 cells was examined in vivo. The PC12 cell line
was stably transfected with a luminally tagged VAMP con-
struct bearing a point mutation in the cytoplasmic tail,
N49A (N49A/PC12). This VAMP derivative shows increased
targeting to SV compared with wild type (Grote et al., 1995).
It shows even more specific targeting to SVs than the
del61-70 mutation used in a previous study (Desnos et al.,
1995). Incubating intact cells at 15
 
8
 
C with iodinated anti-
bodies (
 
125
 
I-KT3) against the lumenal epitope labels plasma
membrane and intracellular compartments without label-
ing synaptic vesicles (Desnos et al., 1995). Internalizing the
antibody at 15
 
8
 
C, removing free antibody, and then incu-
bating the cells at 37
 
8
 
C caused the appearance of anti-
body-labeled SVs, monitored by their migration on glyc-
erol velocity gradients (Fig. 1 
 
a
 
, 
 
s
 
). Free antibody remains
at the top (
 
right
 
) of the velocity gradients. The addition of
BFA (5 
 
m
 
g/ml) inhibited the production of labeled vesicles
upon warming to 37
 
8
 
C (Fig. 1 
 
a
 
, 
 
e
 
). After washing the
drug out, the BFA-mediated block was completely re-
versed within 15 min (Fig. 1 
 
a
 
, 
 
d
 
). The fast reversibility of
the block argues against nonspecific toxicity effects.
BFA was effective at concentrations as low as 0.1 
 
m
 
g/ml
(Fig. 1 
 
b
 
) with a maximal inhibition (80–95%) observed at
concentrations between 5–10 
 
m
 
g/ml (
 
n
 
 
 
5
 
 25). This dose–
Figure 1. In vivo synaptic vesicle biogenesis is inhibited by BFA
in a concentration dependent and reversible way. Stably trans-
fected PC12 cells bearing the N49A VAMP-TAg construct were
labeled at 158C for 40 min in the presence of 125I-KT3 antibody,
and the unbound antibody washed extensively. (a) After washing
out the free antibody, cells were incubated at 08C for 15 min ei-
ther in the absence (s) or presence (e) of BFA (5 mg/ml). Con-
trol and BFA-treated cells were warmed for 15 min. To measure
reversibility, one of the BFA-containing plates was washed thor-
oughly at 08C and then reincubated at 378C for another 15 min in
the absence of BFA (d). The reactions were stopped, cells ho-
mogenized, and high speed supernatants processed for velocity
sedimentation analysis as described in Methods. The data are one
example of two independent experiments. (b) Cells were incu-
bated as described in a with 0.1–10 mg/ml of BFA, and then trans-
ferred at 378C for 15 min and processed as described. BFA inhib-
ited vesicle production in a dose-dependent way (0% inhibition
corresponds to 3550 cpm in the SV peak). 
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response inhibition was similar to that described for the
block of transcytosis in MDCK cells (Hunziker et al.,
1991) and was slightly higher than that required to disrupt
the Golgi complex in fibroblasts (Lippincott-Schwartz et
al., 1991
 
b
 
). In the absence of the drug, the generation of
 
125
 
I-KT3–loaded vesicles from the 15
 
8
 
C compartment
reached a plateau in less than 20 min (Fig. 2 
 
a
 
). Inhibition
by BFA was a fast phenomenon detected as early as 7.5
min (data not shown) and maintained throughout the in-
cubation period (Fig. 2 
 
a
 
). Similar inhibition was obtained
in a PC12 cell line expressing del61–70 VAMP, which also
shows enhanced targeting to SVs (Fig. 2 
 
b
 
; Grote et al.,
1995). Cells transfected with wild-type VAMP showed
similar inhibition (data not shown), but vesicles were la-
beled less efficiently and so the inhibition appeared to be
less dramatic.
The plateau in labeling (Fig. 2) could be due to accumu-
lation of label in a stable, slowly turning over compart-
ment. Alternatively, the plateau could mean that the vesi-
cles recycle and a dynamic equilibrium is reached. To analyze
the turnover time of the 
 
125
 
I-KT3–containing synaptic vesi-
cles, N49A/PC12 cells were labeled at 158C, and then warmed
to 378C for 15 min to allow the formation of 125I-KT3–
loaded SVs. The cells were then incubated at 378C for dif-
ferent times, either in the absence or presence of BFA to
block the formation of newly labeled vesicles. In the ab-
sence of BFA, the amount of SVs decreased slightly after
60 min (Fig. 3, s). In contrast, in BFA-treated cells, the
amount of 125I-KT3–loaded SVs detected in velocity gradi-
ents dropped to 50% in 36 6 2 min (n 5 3) (Fig. 3, e).
About 60% of the labeled SVs disappeared rapidly, indi-
cating that the majority of newly formed SVs are not inert,
but are recycling through a pool that is continuously fed
from a BFA-sensitive compartment.
In Vivo Effects of BFA on the Morphology of the
KT3-labeled VAMP-containing Endosomes
To identify the morphological consequences of BFA treat-
ment, VAMP-TAg N49A–containing endosomes were la-
beled by in vivo uptake of unlabeled KT3 antibody and
examined by confocal immunofluorescence microscopy. In-
tra-cellular labeling was distinguished from plasma mem-
brane labeling by acid stripping the cell surface. Steady-
state KT3-loading at 378C revealed fluorescent signals in
vesicular structures throughout the cytoplasm, with the
strongest labeling in the juxtanuclear region (Fig. 4, A and
B). The internalized fluorescence signal in these compart-
ments was acid resistant (Fig. 4 B). In contrast, after 158C
KT3 labeling, the signal resistant to acid stripping was in
large vesicular structures, some of which were close to the
plasma membrane, others were distributed throughout the
cytosol (Fig. 4 D). No concentration of fluorescent signal
was detected in the juxta- or perinuclear region. However,
if cells labeled at 158C were rewarmed to 378C for 15 min,
the label redistributed to the juxtanuclear region in a pat-
tern similar to the steady-state labeling at 378C (Fig. 4, E,
F, I). These results show that KT3 label moves from the
158C compartment to the perinuclear region. The addition
of BFA before the warming to 378C did not prevent the
accumulation of fluorescent signal in an acid-resistant
compartment around the nucleus (Fig. 4, H and J). No
BFA-induced tubular endosomal structures were distin-
guishable. A similar juxta–perinuclear pattern was ob-
served in cells loaded in BFA at 378C without the 158C
preincubation (Fig. 5 b, C and D). Thus, although both
158C and BFA inhibit SV formation, transport to the peri-
nuclear region is sensitive only to temperature.
The BFA-dependent SV Block Is Selective
Although formation of synaptic vesicles from the 158C
compartment was sensitive to BFA, other parts of the en-
docytotic pathway were not. Internalization of VAMP-
TAg from the cell surface was assessed as acid-resistant
Figure 2. Time course of the BFA inhibition in two VAMP-
transfected PC12 cell lines. Stably transfected PC12 cells bearing
the N49A (a) or del61–70 VAMP-TAg (b) constructs were la-
beled at 158C for 40 min in the presence of 125I-KT3 antibody and
incubated in methanol (0.001%) (s) or BFA (5 mg/ml) (e) as
described. Cells were chased at 378C for different times. The re-
actions were stopped at 08C and the vesicle production was deter-
mined by velocity sedimentation in glycerol gradients as described.
BFA blocked synaptic vesicle biogenesis in both cell lines with no
detectable delay. Similar results were obtained in two indepen-
dent experiments. The amount of SV production at 15 min was
designated as 100%. The radioactivity corresponding to 100%
was 2,000 cpm in a and 10,000 cpm in b.
Figure 3. Newly formed syn-
aptic vesicles turnover. To
evaluate the life span of
newly synthesized synaptic
vesicles, PC12/N49A cells
were labeled with 125I-KT3
antibody at 158C as de-
scribed. The free antibody
was washed at 48C and the
cells were then incubated for
a further 15 min at 378C to al-
low SVs to form. Vesicle bio-
genesis was stopped by plac-
ing cells on ice followed by
treatment in the absence (s)
or presence (e) of BFA (5
mg/ml). After rewarming the
cells back to 378C for different times; the remaining vesicles were
assessed by velocity sedimentation. The data are one example of
three independent experiments.Faúndez et al. Synaptic Vesicle Formation 509
bound  125I-KT3 antibody and found to be similar in the
control and BFA-treated cells (Fig. 5 a). Insensitivity of in-
ternalization to BFA was also shown by immunofluores-
cence (Fig. 5 b). Recycling of transferrin from endosomes
to the cell surface was also relatively unaffected by BFA,
as shown by the kinetics of 125I-labeled rat transferrin recy-
cling from endosomes to the plasma membrane after BFA
treatment (Fig. 6). To measure recycling, 125I-labeled rat
transferrin was internalized at 158C, cells chilled to 48C,
and plasma membrane–associated ligand removed by
washing. Cells were then incubated in the absence or pres-
ence of BFA for different times at 378C. As previously re-
ported in K562 and NRK cells (Lippincott-Schwartz et al.,
1991a; Schonhorn and Wessling-Resnick, 1994), the change
in the rate of transferrin externalization was not very dra-
matic after BFA treatment in N49A/PC12 cells, either eval-
uated as cell-associated radioactivity or released radioactivity.
The drug illimaquinone also inhibits binding of b-COP
and ARF to Golgi membranes, vesicle production, and
protein secretion; but it has no observable effect on the en-
docytic pathway (Takizawa et al., 1993). Illimaquinone
also had no effect on SV formation from 158C-labeled cells
(Fig. 7, 16.3 6 1.7% inhibition, n 5 3) at a concentration
that stops protein traffic through the Golgi complex.
Figure 4. BFA does not prevent the
accumulation of KT3 antibody in peri-
nuclear endosomes. PC12 cells ex-
pressing N49A VAMP-TAg were incu-
bated in the presence of KT3 mAb (10
mg/ml) under different conditions to la-
bel endocytotic organelles. After label-
ing, the cells were chilled, washed ex-
tensively, fixed and processed for
immunofluorescence using a labeled
secondary antibody either before (A,
C,  E, and G) or after (B, D, F, and H–J)
stripping KT3 from the cell surface by
an acid wash. A and B show the total
and internal label when antibody up-
take was permited for 40 min at 378C;
significantly less perinuclear staining
was seen if the uptake was at 158C for
40 min (C and D). BFA did not pre-
vent movement to perinuclear endo-
somes (G, H, and J). If cells were la-
beled at 158C for 40 min, and then
warmed to 378C for 15 min, the distri-
bution of immunofluorescence was
identical whether or not BFA was
present (G, H, and J) or absent (E, F,
and I). I and J represent higher magni-
fications of F and H, respectively. Bars:
10 mm. 
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Higher illimaquinone concentrations or avarol, a structur-
ally similar inhibitor, also did not modify SV production
(data not shown).
Bafilomycin A1, a specific inhibitor of vacuolar type
ATPases, perturbs endosomal pH and membrane traffick-
ing, in both early endosomes and from early to late endo-
somes (van Weert et al., 1995; Aniento et al., 1996). It in-
hibited SV production by 44 
 
6
 
 6% (Fig. 7, 
 
n
 
 
 
5
 
 3). The
inhibition reached a plateau at 250 nM (data not shown).
A similar dose-response has been described in the inhibi-
tion of endocytosis and trafficking of transferrin receptor
back to plasma membrane and in the transfer of markers
from early endosomes to late endosomes (van Weert et al.,
1995; Aniento et al., 1996). These results show that per-
turbing the pH gradients along the endocytic pathway af-
fects SV production but does not mimic the severity of the
BFA effect.
Thus, BFA affects SV formation selectively having no
effect on internalization or recycling of transferrin recep-
tor back to the cell surface. The vacuolar ATPase inhibi-
tor, bafilomycin A1 and illimaquinone, a Golgi-specific in-
hibitor of 
 
b
 
-COP accumulation, are much less effective
inhibitors and have not been studied further.
 
Cell-free SV Biogenesis Requires ARF1 Protein
 
Involvement of ARF1 protein in SV biogenesis was inves-
tigated directly using a cell-free reconstitution assay. ARF1
is believed to interact with effectors through its NH
 
2
 
-ter-
minal domain, since peptides corresponding to its NH
 
2
 
 ter-
minus can block ARF1 function (Balch et al., 1992; Kahn
et al., 1992; Randazzo et al., 1994; Boman and Kahn,
1995). The effects on SV production of an ARF1-derived,
(2–17) NH
 
2
 
-terminus peptide were therefore examined.
In a standard cell-free assay (Desnos et al., 1995), labeled
SVs are generated at 37
 
8
 
C, whereas no production of SV
appears in a reaction at 4
 
8
 
C (Fig. 8, 
 
a
 
 and 
 
c
 
). Under this
condition the addition of a peptide spanning the NH
 
2
 
-ter-
minus effector domain of ARF1 (2–17) at a concentration
of 100 
 
m
 
M, inhibited the SV production by 42 
 
6
 
 4%, (
 
n
 
 
 
5
Figure 5. BFA does not block
the  125I-KT3 internalization.
(a) PC12/N49A cells were sur-
face labeled with 125I-KT3 anti-
body (3.3 mg/ml) for 2 h at 08C.
The unbound label was
washed away and the cells
were incubated in media con-
taining either methanol
(0.001%) (s) or BFA (5 mg/
ml) (e) for 15 min on ice. The
cells were warmed up to 378C
for different times and endocy-
tosis was stopped by putting
the cells back on ice. The inter-
nalized ligand was determined
by surface-acid stripping, and expressed as fraction of the total cell-associated counts. Error bars represent standard deviation of tripli-
cates in one of three independent experiments. (b) Internalization was assessed by immunofluorescent detection of the KT3 antibody
uptake. PC12/N49A cells were incubated with unlabeled antibody for 2 h at 48C and equilibrated in the absence (A and B) or presence
(C and D) of BFA as described in a. Cells were chased at 378C for 15 min. Reactions were stopped at 48C and the total (A and C) and in-
ternalized VAMP-TAg (B and D) determined by acid stripping of the cell surface. Cells were fixed and processed for immunofluores-
cence as described. Bar, 10 mm.
Figure 6. 125I-Transferrin re-
cycling back to the cell sur-
face is not inhibited by BFA.
PC12/N49A endosomes were
labeled with 125I-rat transfer-
rin (0.2 mg/ml) at 158C for 40
min. The free and surface-
bound ligands were removed
by repeated washing fol-
lowed by mild acidic treat-
ment of the cell surface. The
cells were incubated in the
absence (s) or presence of
BFA (5 mg/ml) (e) at 08C in
a media containing 100 mg/ml
of cold rat transferrin and
chased for different times at
378C. Transferrin in the me-
dia (d, r) and in the cells (s, e) was determined as described.
Error bars represent standard errors of triplicate points of one
representative experiment from three independent ones.
Figure 7. Effect of illi-
maquinone and bafilomycin
A1 upon in vivo synaptic ves-
icle biogenesis. PC12/N49A
cells labeled with 125I-KT3
antibody at 158C were incu-
bated for 15 min at 08C either
in the absence or the pres-
ence of the drugs at the con-
centrations indicated. Cells
were then chased at 378C for
15 min, followed by analysis
of the labeled synaptic vesi-
cles by velocity sedimentation. Illimaquinone was almost without
effect (n 5 2), whereas bafilomycin A1 inhibited 44 6 6% (n 5
3) at 1 mM concentration.
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7) (Fig. 8 a). An effect of this magnitude was not detected
using a scrambled peptide of identical composition (105 6
7%, n 5 4) (Fig. 8 a). Since the (2–17) peptide has been re-
ported to inhibit Golgi membrane traffic irreversibly by
damaging membranes (Weidman and Winter, 1994), the
reversibility of its effect upon SV formation was tested.
Identical in vitro reactions containing low levels of brain
cytosol (1 mg/ml) were run in parallel for 15 min at 378C,
in the presence of the scrambled or (2–17) peptide (100
mM). To test reversibility, additional brain cytosol was
added, and the incubation continued at 378C for another
15 min. Inhibition by (2–17) peptide was reversed by add-
ing more cytosol (Fig. 8 b), indicating that if the peptide
concentration was 100 mM or less, the inhibitory effect was
not solely due to membrane damage. Since this peptide is
able to inhibit ARF-independent processes (Fensome et
al., 1994), we tested if the addition of wild-type ARF1
could induce a recovery of the (2–17) peptide inhibitory
effect on SV formation. In standard reactions containing
100 mM of (2–17) peptide, the addition of 50 mM myristoy-
lated wild-type ARF1 together with the peptide (Fig. 8 c)
decreased the inhibition to 24 6 10 (n 5 3). These results
show a competitive interaction between ARF1 and the
peptide, and imply that an ARF is involved in the budding
reaction.
To further address ARF1 involvement, we tested the ef-
fects of purified ARF1 mutants Q71L, a GTPase null, and
T31N (a GTP-binding defective mutant) on the formation
of properly sized SVs, assessed by velocity gradient sedi-
mentation. The amount of labeled SVs was unchanged by
supplementing the standard reaction mixtures with 50 mM
wild-type ARF1 (Fig. 9 a). In contrast, in standard reac-
tions supplemented with 50 mM of either dominant-posi-
tive (Q71L) or dominant-negative (T31N) mutants, there
was a drastic reduction in the amount of labeled vesicles
detected in velocity gradients. Both recombinant mutant
proteins were effective at concentrations as low as 1 mM
(Fig. 9 b). This concentration is similar to the amount of
ARF1 estimated to be present in the rat brain cytosol used
in the standard reaction mixtures (data not shown; Kahn
et al., 1988). Consistently Q71L was more potent when
compared with T31N. Both mutants were also able to in-
duce a reduction in the production of labeled SVs in the
suboptimal conditions when only PC12 cell cytosol is
present without added brain cytosol (Desnos et al., 1995).
Even under these conditions, however, additional wild-
type ARF1 had no stimulatory effect (data not shown), in-
dicating that the endogenous ARF1 protein present in the
PC12 extracts was sufficient for the vesicle budding reaction.
To demonstrate ARF dependence directly, the cell-free
assay was changed by removing the ARF1 present in rat
brain cytosol. This was done by passing the cytosol
through a Superose 6 sizing column and taking high mo-
lecular weight (HMW) fractions reported to be enriched
in coat complexes (Stamnes and Rothman, 1993; data not
shown). These HMW fractions were pooled and added to
the cell-free reaction in the absence of added rat brain cy-
tosol. The addition of HMW fractions alone stimulated the
Figure 8. The ARF1 NH2-
terminus peptide (2–17) re-
versibly inhibits synaptic ves-
icle biogenesis in a cell-free
system. Standard reaction
mixtures containing homoge-
nates from PC12/N49A cells
labeled with 125I-KT3 anti-
body at 158C, ATP regener-
ating system, and rat brain
cytosol (1 mg/ml or 0.35 mg/
assay) were prepared and
kept on ice for 15 min, either
in the absence or presence of
the (2–17) NH2-terminus
peptide, or the control
scrambled peptide. Budding
reactions were initiated by
warming for 30 min at 378C.
Vesicle production was as-
sessed by velocity sedimenta-
tion as described. (a) The (2–
17) NH2-terminus peptide
(100  mM) inhibited the gen-
eration of vesicles by 42 6
4% of control. a Shows a rep-
resentative experiment out
of seven experiments. The
random peptide had no ef-
fect on the budding reaction at the highest concentration tested (200 mM). In b, the inhibitory effect of the (2–17) NH2-terminus peptide
(100 mM) was reverted by adding additional cytosol. Reaction mixtures similar to those described in a were incubated at 08C either with
(2–17) NH2 terminus or the scrambled peptide (100 mM) for 15 min. The reactions were warmed at 378C for 15 min, and then supple-
mented or not with more cytosol. The reactions were allowed to proceed for an additional 15 min before being stopped and analyzed.
Dilution of peptide by the addition of cytosol did not exceed 20%. In c, the inhibition mediated by the (2–17) NH2-terminus peptide was
reversed by the addition of purified myristoylated recombinant wild-type ARF1 (50 mM).The Journal of Cell Biology, Volume 138, 1997 512
formation of vesicles by 1.7 6 0.15 times (n 5 5). However
the combined addition of HMW fractions plus myristoy-
lated wild-type ARF1 increased the vesicle production 2.6
6 0.15 times. Further, both mutant ARFs inhibited the ap-
pearance of vesicles in the presence of HMW (Fig. 10).
These results show that ARF1 is required for SV biogene-
sis. A likely possibility is that it recruits coating molecules
present in the HMW fraction.
ARF molecules have been implicated in recruiting coats
made up either of coatomers or of adaptor/clathrin com-
plexes. To test if clathrin was involved in the budding pro-
cess, it was quantitatively removed from rat brain cytosol
using mAb to clathrin (Fig. 11 a). No significant reduction
in budding efficiency was observed (Fig. 11 b). To examine
the involvement of COPI coatomers in vesicle formation,
we used conditions that are known to inhibit COPI func-
tion during endosomal sorting (Whitney et al., 1995) or
binding of COPI to membranes (Lowe and Kreis, 1995).
Addition of antibodies to b-COP, a fusion protein corre-
sponding to the KKXX signal motif of WBPI (GST-KK)
(Cosson and Letourneur, 1994), or a combination of the
antibody and the inhibitory peptide had no effect on vesi-
cle formation.
Q71L and T31N ARF1 Mutants Define Different 
Intermediates in SV Biogenesis
A current model for the mechanism of action of the GTP-
ase-defective mutant Q71L on Golgi membranes predicts
that both ARF and coats remain constitutively associated
with the membranes coming from the donor compartment,
while the GTP-binding defect in T31N precludes the asso-
ciation of both ARF and coats to the donor membranes
(Donaldson and Klausner, 1994; Rothman and Wieland,
1996; Schekman and Orci, 1996). Thus the T31N mutation
should prevent coating of the donor compartment and the
Q71L mutant should cause extensive coating of a donor
compartment or the accumulation of a coated vesicular in-
termediate. The nature of the 158C donor compartment
has been extensively studied (Lichtenstein, Y., C. Desnos,
V. Faúndez, R.B. Kelly, and L. Clift-O’Grady, manuscript
in preparation). From a postnuclear supernatant of la-
beled PC12 cells the donor compartment could be recov-
ered at 31.4 6 0.3% (n 5 13) sucrose. About 40% of the
donor peak was converted in vitro to SVs, which are re-
covered at 24% sucrose under the same conditions. When
the in vitro reaction was performed, in the presence of
Q71L or T31N ARF1, no peak of label was observed at
the density of SVs (24% sucrose). Instead, the donor
membranes became lighter in the presence of T31N and
denser in the presence of Q71L. The donor membranes ac-
quired a density of 28.6 6 0.8% sucrose (n 5 3) in the
presence of T31N and 33.3 6 0.7% sucrose (n 5 3) in the
presence of Q71L. This would be consistent with a model
in which the donor compartment lost some coat during in-
cubation with T31N. Donor membranes from cells labeled
at 378C in the presence of BFA are also light (27.5 6 0.7, n 5
2) (data not shown). The increase in density of the donor
membranes in the presence of Q71L could be attributed to
either the recruitment of additional coat to the donor en-
Figure 9. Dominant-positive and -negative mutant ARF1 inhibit
the appearance of mature synaptic vesicles in a cell-free system.
Standard reaction mixtures similar to those described in Fig. 8
were performed in the absence or presence of recombinant
myristoylated wild-type, Q71L (dominant positive), and T31N
(dominant negative) proteins. The ARF1 proteins incubated with
the reaction mixes for 15 min at 08C and then warmed to 378C for
30 min. (a) At 50 mM, both Q71L (n) and T31N (---s---) inhib-
ited the appearance of matured vesicles as assessed in velocity
sedimentation compared to control (—s—). The addition of
wild-type ARF1 (e) was without effect on the vesicle production.
Vesicle production did not occur at 48C ( ). In b dominant-nega-
tive and -positive mutant forms of ARF1 were added at concen-
trations ranging from 1 to 50 mM. The maximal inhibitory effect
was reached by 5 mM for both of them (0% inhibition corre-
sponds to 8,157 cpm).
Figure 10. ARF1 stimulates
the SV budding activity in a
cell-free system in the pres-
ence of a HMW fraction
from rat brain cytosol. If
brain cytosol was omitted
from standard reaction mix-
tures that contained labeled
N49A/PC12 cell homoge-
nates and ATP, little SV pro-
duction was observed during
a 30 min incubation at 378C
(s). The cytosol-free reac-
tion was stimulated slightly
( ) by the addition of
ARF1-depleted, HMW frac-
tions (650 mg/assay) from Su-
perose 6–fractionated rat
brain cytosol. Under these
conditions a direct stimula-
tion of SV production by 15
mM of wild-type, myristoy-
lated ARF1 could be ob-
served (e) added before the cell-free budding reaction. Addition
of 15 mM T31N ARF1 (s) inhibited the reaction to approxi-
mately the cytosol-free level whereas Q71L ARF1 (n) inhibited
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dosomal compartment, or the formation of a coated vesi-
cle intermediate.
Discussion
By using BFA, wild-type, and mutant ARF1 proteins, we
have demonstrated that ARF1 is required for the forma-
tion of SVs in PC12 cells from the 158C compartment. The
physiological relevance of ARF1 involvement in PC12 SV
formation is supported by several arguments. In vivo SV
formation is reversibly sensitive to BFA at concentrations
known to affect budding from Golgi membranes. The inhi-
bition occurs in three PC12 clones expressing different
forms of VAMP. The number of SVs is reduced in PC12
cells incubated in the presence of BFA. ARF1 and a cyto-
sol-derived HMW fraction are sufficient to promote SV
production from a PC12 homogenate. Micromolar concen-
trations of mutant recombinant ARF1s block SV forma-
tion; and cell-free incubation of homogenates in the pres-
ence of a GTP-binding defective mutant of ARF1 generates
antibody-loaded compartments of density different to
those formed in the presence of a GTPase-defective mu-
tant. Since most of the ARF1 isoforms are functionally
equivalent (Kahn et al., 1991; Boman and Kahn, 1995),
however, we cannot be certain that only ARF1 is involved
in SV formation.
Specialized Endosomal Compartments as a Source
of SV?
BFA has been useful in characterizing functionally spe-
cialized endosomes in polarized cells. In MDCK cells and
in primary hippocampal neuron cultures, transfer of pIgA
from apical/perikaryal endosomes to the apical/axonal
membrane exhibits a BFA sensitivity similar to that ob-
tained in SV production (Hunziker et al., 1991; Barroso
and Sztul, 1994; de Hoop et al., 1995). However, BFA ef-
fects on nonspecialized endocytic routes are subtle. Al-
though BFA induces morphological alterations in endo-
somes, it does not block the transit of dyes to lysosomes or
the recycling of transferrin back to the cell surface (Lip-
pincott-Schwartz et al., 1991a; Tooze and Holinshead,
1992; Wood and Wood, 1992; Schonhorn and Wessling-
Resnick, 1994). The transferrin externalization rate is slowed
but not blocked by BFA (Schonhorn and Wessling-
Resnick, 1994; Fig. 6). In addition to being BFA sensitive,
the transit of proteins through apical/perikaryal endo-
somes and through synaptic vesicle-generating endosomes
are both unusually sensitive to low temperature blocks
(15–178C) (Barroso and Sztul, 1994; Desnos et al., 1995).
This suggests that the specialized pathways in epithelia
and neuronal cells may use a temperature-sensitive “coat-
ing” function, absent from nonspecialized or “housekeep-
ing” pathways.
The endosomes of nerve terminals in primary hippo-
campal neurons (Mundigl et al., 1993) and of processes in
differentiated PC12 cells (Bonzelius et al., 1994) are spe-
cialized compared with those in the cell body, particularly
in their lack of transferrin receptor. Although it would be
tempting to conjecture that these axonal endosomes might
be more BFA sensitive, morphological data show that
BFA causes tubulation of cell body but not axonal endo-
somes (Mundigl et al., 1993). One interpretation of such
data is that the BFA-sensitive pathway of SV biogenesis in
PC12 cells represents a more elementary form of biogene-
sis that is replaced in nerve terminal maturation with a
more efficient and uniquely neuronal process. Alternative
explanations are that the two pathways exist side by side in
neurons, or the biogenesis of neuroendocrine SVs might
be mechanistically unrelated to the biogenesis of neuronal
SVs. Further experiments are required to distinguish be-
tween these alternatives.
PC12 SVs Are Dynamic Organelles
In immature hippocampal nerve cells, SVs go through a
spontaneous rate of fusion with the plasma membrane in
the absence of stimulation (Matteoli et al., 1992). Our re-
sults provide evidence that newly formed SVs in PC12
cells also cycle in the absence of stimulation. After loading
the cells at 158C, the production of vesicles at 378C reaches
a maximum in about 15 min. This equilibrium represents a
balance between the kinetics of formation and disappear-
ance. When the SV pool of PC12 cells is labeled at 378C,
and BFA added to suppress further SV formation, about
half the vesicles disappear in 30 min. Although this reduc-
tion of labeled vesicles is probably due to exocytosis, it
could also be due to fusion back to the donor or to other
intracellular membrane compartments. BFA inhibition in
vivo (Figs. 1 and 2) could be attributed to an enhancement
of exocytosis rather than fusion. This is unlikely however,
since BFA (data not shown) and ARF mutants block SV
formation in cell-free assays, where fusion with the plasma
membrane is not probable.
Figure 11. Cytosolic clathrin
and COPI are not needed for
the cell-free budding of SV.
(a) Normal rat brain cytosol
was immunodepleted of
clathrin heavy chains using
the X22 mAb bound to pro-
tein G–Sepharose. The ex-
tent of depletion was con-
firmed by immunoblotting
equal amounts of rat brain
cytosol protein before (lane
1) or after (lane 2) the immu-
noabsorption with the TD.1
anti-clathrin antibody. Lane
3 corresponds to clathrin
heavy chains retained on the
beads. (b) In vitro reaction
mixtures were prepared con-
taining labeled N49A/PC12
cell homogenates, ATP re-
generating system in the pres-
ence of normal or clathrin-
depleted rat brain cytosol.
Reactions containing normal rat brain cytosol (supplemented
with either 11–22 mg/ml of affinity-purified anti–b-COP antipep-
tide antibody EAGE, 1 mM of either GST-WBP1-SS or GST-
WBP1-KK, or a combination of EAGE antibody plus GST-
WBP1-KK) were kept for at least 3 h at 48C before warming to
378C. None of the treatments substantially modified the budding
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A Possible Mechanism of SV Biogenesis Revealed by 
ARF1 Mutants
It has been proposed that ARF-GTP recruits coats to the
nascent vesicle that is budding from precursor Golgi mem-
branes (Serafini et al., 1991; Rothman and Wieland, 1996).
In Golgi- and ER-derived membranes, the ARF-GTPase
activity is required for the uncoating of already formed
vesicles (Tanigawa et al., 1993; Bednarek et al., 1995;
Rothman and Wieland, 1996). Preventing GTP hydrolysis
results in the formation of carrier vesicles that contain ma-
ture cargo and fusion proteins but retain their coats (Os-
termann et al., 1993; Oka and Nakano, 1994; Bednarek et
al., 1995; Rothman and Wieland, 1996). Since GTPgS ef-
fects are pleiotropic and can induce mistargeting of the
adaptor (Seaman et al., 1993), the Q71L mutant is more
informative for in vitro studies. For example, Q71L ARF
can discriminate COPI- and II-dependent budding events
simultaneously occurring from yeast ER (Bednarek et al.,
1995).
Formation of SVs in a cell-free system resembles the
production of Golgi-derived vesicles in its sensitivity to
GTPgS (Desnos et al., 1995), its sensitivity to BFA and the
need for ARF and a HMW protein fraction. If the inhibi-
tion of SV formation by the ARF mutants is interpreted in
light of the Golgi results, then the mutant T31N ARF is
predicted to prevent the binding of coat and ARF to mem-
branes, and the Q71L ARF mutant would allow coated
vesicles to form, but prevent their uncoating. Consistent
with those predictions, the donor membranes became less
dense when incubated in vitro with T31N ARF, and
denser when incubated with Q71L. Unfortunately, the
quantities of membrane currently available and their con-
tamination with nondonor membranes preclude biochemi-
cal analyses of the two intermediate forms.
If ARFs were recruiting a coat to the SV precursor
membranes, the coat would be expected to be clathrin
(Heuser and Reese, 1973; Shupliakov et al., 1997). We could,
however, find no evidence that the factor or factors con-
tributed by rat brain cytosol were either clathrin or COPI.
The data do not eliminate the involvement of either coat
in budding, however, since sufficient coat molecules may
remain attached to the donor membranes. Peripheral pro-
teins removed from PC12 donor membranes by Tris-strip-
ping are able to support the in vitro budding reaction
(Horng, J.-T., unpublished observations). Unfortunately
the quantities of proteins extractable from PC12 mem-
branes using Tris are too small for detailed analysis. The
active components in the rat brain cytosol are unlikely to
include dynamin because extensive depletion using a grb2
affinity column also has no effect on SV formation in vitro
(Horng, J.-T., unpublished observations). One possible coat
that remains to be tested is the AP-3 coat, implicated in
post-Golgi, and probably endosomal sorting events (Simp-
son et al., 1996; Dell’Angelica et al., 1997). It is also possi-
ble that the donor compartments contain partially coated
vesicles. The addition of ARF and the high molecular
weight fraction could complete the coat, allowing uncoat-
ing to proceed. Alternatively, the synaptic vesicle precur-
sor could be a complete coated vesicle that accumulated at
158C. For this model to be plausible, the T31N dominant
negative ARF1 mutant and BFA must inhibit uncoating as
well as coating, a property that has not heretofore been at-
tributed to ARF and to BFA.
It has been noted that Golgi budding in some cell types,
such as MDCK cells, is BFA-resistant and does not re-
quire the addition of exogenous ARF (Ktistakis et al., 1995,
1996). The formation of SVs more closely resembles bud-
ding from CHO Golgi membranes in its BFA and exoge-
nous ARF sensitivity. Examination of Golgi budding in
the BFA-resistant cell types generated evidence that the
role of ARF is catalytic, not stoichiometric and involves
the activation of phospholipase D activity by ARF (Brown
et al., 1993). The role, if any, of phospholipiase D in SV
formation needs to be examined further.
In summary, our data show that SV biogenesis in PC12
cells is a process that requires ARF and that the GTP/GDP
status of the ARF regulates the intermediates with which it
is associated. Because the ARF family is so strongly linked
to coating events, our data strongly suggest the participa-
tion of coat proteins in the budding of synaptic vesicles
from PC12 membranes. The next step is to identify the
proteins to which ARF1 binds, and the coating molecules
that are recruited.
We thank Dr. F. Brodsky (University of California, San Francisco, CA
[UCSF]) for the generous gift of antibodies to clathrin (X-22) and TD.1.
Dr. T. Kreis (University of Geneva, Switzerland) kindly provided antibod-
ies to b-COP (EAGE), and Dr. F. Letourneur (Basel Institute for Immu-
nology, Switzerland) provided fusion proteins GST-WBP1-KK and GST-
WBP1-SS. We are also grateful to Drs. L. Nagy (University of Guelph,
Ontario, Canada) and J. Roos (UCSF) for their helpful comments in the
initial preparation of the manuscript.
Funded by National Institutes of Health (NIH) grants NS09878,
NS15927, and DA10154 to R.B. Kelly. V. Faundez is the recipient of a
NIH Fogarty International Postdoctoral Fellowship.
Received for publication 17 January 1997 and in revised form 11 June
1997.
References
Aniento, F., F. Gu, R.G. Parton, and J. Gruenberg. 1996. An endosomal bCOP
is involved in the pH-dependent formation of transport vesicles destined for
late endosomes. J. Cell Biol. 133:29–41.
Balch, W.E., R.A. Kahn, and R. Schwaninger. 1992. ADP-ribosylation factor is
required for vesicular trafficking between the endoplasmic reticulum and the
cis-Golgi compartment. J. Biol. Chem. 267:13053–13061.
Barroso, M., and E.S. Sztul. 1994. Basolateral to apical transcytosis in polarized
cells is indirect and involves BFA and trimeric G protein sensitive passage
through the apical endosome. J. Cell Biol. 124:83–100.
Bednarek, S.Y., M. Ravazzola, M. Hosobuchi, M. Amherdt, A. Perrelet, R.
Schekman, and L. Orci. 1995. COPI- and COPII-coated vesicles bud directly
from the endoplasmic reticulum in yeast. Cell. 83:1183–1195.
Boman, A.L., and R.A. Kahn. 1995. Arf proteins: the membrane traffic police?
Trends Biochem. Sci. 20:147–150.
Bonzelius, F., G.A. Herman, M.H. Cardone, K.E. Mostov, and R.B. Kelly.
1994. The polymeric immunoglobulin receptor accumulates in specialized
endosomes but not synaptic vesicles within the neurites of transfected neu-
roendocrine PC12 cells. J. Cell Biol. 127:1603–1616.
Brodsky, F.M. 1985. Clathrin structure characterized with monoclonal antibod-
ies. I. Analysis of multiple antigenic sites. J. Cell Biol. 101:2047–2054.
Brown, H.A., S. Gutowski, C.R. Moomaw, C. Slaughter, and P.C. Sternweis.
1993. ADP-ribosylation factor, a small GTP-dependent regulatory protein,
stimulates phospholipase D activity. Cell. 75:1137–1144.
Cavenagh, M.M., J.A. Whitney, K. Carroll, J.J. Zhang, A.L. Boman, A.G.
Rosenwald, I. Mellman, and R.A. Kahn. 1996. Intracellular distribution of
Arf proteins in mammalian cells. J. Biol. Chem. 271:21767–21774.
Chen, Y.-G., and D. Shields. 1996. ADP-ribosylation factor-1 stimulates forma-
tion of nascent secretory vesicles from the trans-Golgi network of endocrine
cells. J. Biol. Chem. 271:5297–5300.
Cosson, P., and F. Letourneur. 1994. Coatomer interaction with di-lysine endo-
plasmic reticulum retention motifs. Science (Wash. DC). 263:1629–1631.
De Camilli, P., and K. Takei. 1996. Molecular mechanisms in synaptic vesicle
endocytosis and recycling. Neuron. 16:481–486.Faúndez et al. Synaptic Vesicle Formation 515
de Hoop, M., C. von Poser, C. Lange, E. Ikonen, W. Hunziker, and C.G. Dotti.
1995. Intracellular routing of wild type and mutated polymeric immunoglob-
ulin receptor in hippocampal neurons in culture. J. Cell Biol. 130:1447–1459.
Dell’Angelica, E.C., H. Ohno, C.E. Ooi, E. Rabinovich, K.W. Roche, and J.S.
Bonifacino. 1997. AP-3: an adaptor-like protein complex with ubiquitous ex-
pression. EMBO (Eur. Mol. Biol. Organ.) J. 16:917–928.
Desnos, C., L. Clift-O’Grady, and R.B. Kelly. 1995. Biogenesis of synaptic vesi-
cles in vitro. J. Cell Biol. 130:1041–1049.
Dittie, A.S., N. Hajibagheri, and S.A. Tooze. 1996. The AP-1 adaptor complex
binds to immature secretory granules from PC12 cells and is regulated by
ADP-ribosylation factor. J. Cell Biol. 132:523–536.
Donaldson, J.G., and R.D. Klausner. 1994. ARF-a key regulatory switch in
membrane traffic and organelle structure. Curr. Opin. Cell Biol. 6:527–532.
Donaldson, J.G., D. Finazzi, and R.D. Klausner. 1992. Brefeldin A inhibits
Golgi membrane-catalysed exchange of guanine nucleotide onto ARF pro-
tein. Nature (Lond.). 360:350–352.
Fensome, A., E. Cunningham, O. Troung, and S. Cockcroft. 1994. ARF(2-17)
does not specifically interact with ARF1-dependent pathways. Inhibition by
peptide of phospholipases Cb, D and exocytosis in HL60 cells. FEBS (Fed.
Eur. Biochem. Soc.) Letts. 349:34–38.
Grote, E., and R.B. Kelly. 1996. Endocytosis of VAMP is facilitated by a synap-
tic vesicle targeting signal. J. Cell Biol. 132:537–549.
Grote, E., J.C. Hao, M.K. Bennett, and R.B. Kelly. 1995. A targeting signal in
VAMP regulating transport to synaptic vesicles. Cell. 81:581–589.
Helms, J.B., and J.E. Rothman. 1992. Inhibition of brefeldin A of a Golgi mem-
brane enzyme that catalyses exchange of guanine nucleotide bound to ARF.
Nature (Lond.). 360:352–354.
Heuser, J.E., and T.S. Reese. 1973. Evidence for recycling of synaptic vesicle
membrane during transmitter release at the frog neuromuscular junction. J.
Cell Biol. 37:315–344.
Hunziker, W., J.A. Whitney, and I. Mellman. 1991. Selective inhibition of trans-
cytosis of brefeldin A in MDCK cells. Cell. 67:617–627.
Kahn, R.A., C. Goddard, and M. Newkirk. 1988. Chemical and immunological
characterization of the 21-kDa ADP-ribosylation factor of adenylate cy-
clase.  J. Biol. Chem. 263:8282–8287.
Kahn, R.A., F.G. Kern, J. Clark, E.P. Gelmann, and C. Rulka. 1991. Human
ADP-ribosylation factors. A functionally conserved family of GTP-binding
proteins. J. Biol. Chem. 266:2606–2614.
Kahn, R.A., P. Randazzo, T. Serafini, O. Weiss, C. Rulka, J. Clark, M. Am-
herdt, P. Roller, L. Orci, and J.E. Rothman. 1992. The amino terminus of
ADP-ribosylation factor (ARF) is a critical determinant of ARF activities
and is a potent and specific inhibitor of protein transport. J. Biol. Chem. 267:
13039–13046.
Ktistakis, N.T., H.A. Brown, P.C. Sternweis, and M.G. Roth. 1995. Phospholi-
pase D is present on Golgi-enriched membranes and its activation by ADP
ribosylation factor is sensitive to brefeldin A. Proc. Natl. Acad. Sci. USA. 92:
4952–4956.
Ktistakis, N.T., H.A. Brown, M.G. Waters, P.C. Sternweis, and M.G. Roth.
1996. Evidence that phospholipase D mediates ADP ribosylation factor-
dependent formation of Golgi coated vesicles. J. Cell Biol. 134:295–306.
Lippincott-Schwartz, J., L. Yuan, C. Tipper, M. Amherdt, L. Orci, and R.D.
Klausner. 1991a. Brefeldin A’s effects on endosomes, lysosomes and the
TGN suggest a general mechanism for regulating organelle structure and
membrane traffic. Cell. 67:601–616.
Lippincott-Schwartz, J., J. Glickman, J.G. Donaldson, J. Robbins, T.E. Kreis,
K.B. Seamon, M.P. Sheetz, and R.D. Klausner. 1991b. Forskolin inhibits and
reverses the effects of brefeldin A on Golgi morphology by a cAMP-inde-
pendent mechanism. J. Cell Biol. 112:567–577.
Lowe, M., and T.E. Kreis. 1995. In vitro assembly and disassembly of coatomer.
J. Biol. Chem. 270:31364–31371.
Martys, J.L., T. Shevell, and T.E. McGraw. 1995. Studies of transferrin recy-
cling reconstituted in streptolysin O permeabilized chinese hamster ovary
cells. J. Biol. Chem. 270:25976–25984.
Matteoli, M., K. Takei, M.S. Perin, T.C. Sudhof, and P. De Camilli. 1992. Exo-
endocytotic recycling of synaptic vesicles in developing processes of cultured
hippocampal neurons. J. Cell Biol. 117:849–861.
Mundigl, O., M. Matteoli, L. Daniell, A. Thomas-Reetz, A. Metcalf, R. Jahn,
and P. De Camilli. 1993. Synaptic vesicle proteins and early endosomes in
cultured hippocampal neurons: differential effects of brefeldin A in axon
and dendrites. J. Cell Biol. 122:1207–1221.
Narula, N., and J.L. Stow. 1995. Distinct coated vesicles labeled for p200 bud
from trans-Golgi network membranes. Proc. Natl. Acad. Sci. USA. 92:2874–
2878.
Nathke, I.S., J. Heuser, A. Kupas, J. Stock, C.W. Turck, and F.M. Brodsky.
1992. Folding and trimerization of clathrin subunits at the triskelion hub.
Cell. 68:899–910.
Oka, T., and A. Nakano. 1994. Inhibition of GTP hydrolysis by Sar1p causes ac-
cumulation of vesicles that are a functional intermediate of the ER-to-Golgi
transport in yeast. J. Cell Biol. 124:425–434.
Ostermann, J., L. Orci, K. Tani, M. Amherdt, M. Ravazzola, Z. Elazar, and J.E.
Rothman. 1993. Stepwise assembly of functionally active transport vesicles.
Cell. 75:1015–1025.
Randazzo, P.A., O. Weiss, and R.A. Kahn. 1992. Preparation of recombinant
ADP-ribosylation factor. Methods Enzymol. 219:362–369.
Randazzo, P.A., T. Terui, S. Sturch, and R.A. Kahn. 1994. The amino terminus
of ADP-ribosylation factor (ARF) I is essential for interaction with Gs and
ARF GTPase-activating protein. J. Biol. Chem. 269:29490–29494.
Robinson, M.S., and T.E. Kreis. 1992. Recruitment of coat proteins onto Golgi
membranes in intact and permeabilized cells: effects of brefeldin A and G
protein activators. Cell. 69:129–138.
Rothman, J.E., and F.T. Wieland. 1996. Protein sorting by transport vesicles.
Science (Wash. DC). 272:227–234.
Salama, N.R., T. Yeung, and R.W. Schekman. 1993. The Sec13p complex and
reconstitution of vesicle budding from the ER with purified cytosolic pro-
teins. EMBO (Eur. Mol. Biol. Organ.) J. 12:4073–4082.
Schekman, R., and L. Orci. 1996. Coat proteins and vesicle budding. Science
(Wash. DC). 271:1526–1533.
Schonhorn, J.E., and M. Wessling-Resnick. 1994. Brefeldin A down-regulates
the transferrin receptor in K562 cells. Mol. Cell. Biochem. 135:159–169.
Seaman, M.N., C.L. Ball, and M.S. Robinson. 1993. Targeting and mistargeting
of plasma membrane adaptors in vitro. J. Cell Biol. 123:1093–1105.
Serafini, T., L. Orci, M. Amherdt, M. Brunner, R.A. Kahn, and J.E. Rothman.
1991. ADP-ribosylation factor is a subunit of the coat of Golgi-derived COP-
coated vesicles: a novel role for a GTP-binding protein. Cell. 67:239–253.
Shupliakov, O., P. Loew, D. Grabs, H. Gad, H. Chen, C. David, K. Takei, P. De
Camilli, and L. Brodin. 1997. Synaptic vesicle endocytosis impaired by dis-
ruption of Dynamin-SH3 domain interactions. Science (Wash. DC). 276:259–
263.
Simon, J.-P., I.E. Ivanov, B. Shopsin, D. Hersh, M. Adesnik, and D.D. Sabatini.
1996. The in vitro generation of post-Golgi vesicles carrying viral envelope
glycoproteins requires an ARF-like GTP-binding protein and a protein ki-
nase C associated with the Golgi apparatus. J. Biol. Chem. 271:16952–16961.
Simpson, S., N.A. Bright, M.A. West, L.S. Newman, R.B. Darnell, and M.S.
Robinson. 1996. A novel adaptor-related protein complex. J. Cell Biol. 133:
749–760.
Stamnes, M.A., and J.E. Rothman. 1993. The binding of AP-1 clathrin adaptor
particles to Golgi membranes requires ADP-ribosylation factor, a small
GTP-binding protein. Cell. 73:999–1005.
Takei, K., O. Mundigl, L. Daniell, and P. De Camilli. 1996. The synaptic vesicle
cycle: a single vesicle budding step involving clathrin and dynamin. J. Cell
Biol. 133:1237–1250.
Takizawa, P.A., J.K. Yucel, B. Veit, D.J. Faulkner, T. Deerinck, G. Soto, M. El-
lisman, and V. Malhotra. 1993. Complete vesiculation of Golgi membranes
and inhibition of protein transport by a novel sea sponge metabolite, ili-
maquinone. Cell. 73:1079–1090.
Tanigawa, G., L. Orci, M. Amherdt, M. Ravazzola, J.B. Helms, and J.E. Roth-
man. 1993. Hydrolysis of bound GTP by ARF protein triggers uncoating of
Golgi-derived COP-coated vesicles. J. Cell Biol. 123:1365–1371.
Tooze, J., and M. Holinshead. 1992. In AtT20 and HeLa cells brefeldin A in-
duces the fusion of tubular endosomes and changes their distribution and
some of their endocytic properties. J. Cell Biol. 118:813–830.
van Weert, A.W.M., K.W. Dunn, H.J. Geuze, F.R. Maxfield, and W. Stoorvo-
gel. 1995. Transport from late endosomes to lysosomes but not sorting of in-
tegral membrane proteins in endosomes, depends on the vacuolar proton
pump. J. Cell Biol. 130:821–834.
Walker, M.W., D.A. Bobak, S.C. Tsai, J. Moss, and M. Vaughan. 1992. GTP but
not GDP analogues promote association of ADP-ribosylation factors, 21-
kDa protein activators of cholera toxin, with phospholipids and PC-12 cell
membranes. J. Biol. Chem. 267:3230–3235.
Waters, M.G., T. Serafini, and J.E. Rothman. 1991. ‘Coatomer’: a cytosolic pro-
tein complex containing subunits of non-clathrin-coated Golgi transport ves-
icles. Nature (Lond.). 349:248–251.
Weidman, P.J., and W.M. Winter. 1994. The G protein-activating peptide, mas-
toparan, and the synthetic NH2-terminal ARF peptide, ARFp13, inhibit in
vitro Golgi transport by irreversibly damaging membranes. J. Cell Biol. 127:
1815–1827.
Whitney, J.A., M. Gomez, D. Sheff, T.E. Kreis, and I. Mellman. 1995. Cytoplas-
mic coat proteins involved in endosome function. Cell. 83:703–713.
Wood, S.A., and W.J. Wood. 1992. The morphology but not the function of en-
dosomes and lysosomes is altered by brefeldin A. J. Cell Biol. 119:273–285.
Wood, S.A., J.E. Park, and W.J. Brown. 1991. Brefeldin A causes a microtu-
bule-mediated fusion of the trans-Golgi network and early endosomes. Cell.
67:591–600.